207 related articles for article (PubMed ID: 27408946)
1. ARAs to the RESCUE.
Kaplan NM
J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
[No Abstract] [Full Text] [Related]
2. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
3. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Derer W; Dechend R; Müller DN
MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
[No Abstract] [Full Text] [Related]
4. Mineralocorticoid receptor antagonists and endothelial function.
Maron BA; Leopold JA
Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
7. Treatment considerations with aldosterone receptor antagonists.
Sica DA; Flack JM
J Clin Hypertens (Greenwich); 2011 Jan; 13(1):65-9. PubMed ID: 21214724
[No Abstract] [Full Text] [Related]
8. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone receptor antagonists: effective but often forgotten.
Maron BA; Leopold JA
Circulation; 2010 Feb; 121(7):934-9. PubMed ID: 20177008
[No Abstract] [Full Text] [Related]
10. Hypertension, angiotensin II, aldosterone, and race.
Ben-Yehuda O
J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
[No Abstract] [Full Text] [Related]
11. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Struthers A; Krum H; Williams GH
Clin Cardiol; 2008 Apr; 31(4):153-8. PubMed ID: 18404673
[TBL] [Abstract][Full Text] [Related]
14. [Aldosterone antagonists--first choice in resistant hypertension].
Holzgreve H
MMW Fortschr Med; 2016 Apr; 158(7):65-6. PubMed ID: 27071591
[No Abstract] [Full Text] [Related]
15. Eplerenone. Pharmacia.
Liew D; Martin J; Krum H
Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone: a review of its use in essential hypertension.
Croom KF; Perry CM
Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
[TBL] [Abstract][Full Text] [Related]
17. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
[TBL] [Abstract][Full Text] [Related]
18. Eplerenone for the treatment of cardiovascular disorders.
Watanabe M; Krum H
Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
[TBL] [Abstract][Full Text] [Related]
19. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
Danjuma MI; Mukherjee I; Makaronidis J; Osula S
Curr Hypertens Rep; 2014 Feb; 16(2):414. PubMed ID: 24407447
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
